The treatment of Kyrle's disease: a systematic review

Kyrle's disease (KD) is a cutaneous disease that develops in individuals with underlying systemic disease, particularly chronic renal failure and diabetes mellitus (DM), and is associated with a high burden of disease linked to itch. The intensely pruritic, hyperkeratotic papulonodular rash seen in KD dramatically impairs patients’ quality of life and increases their risk of mortality. Unfortunately, no guidelines or evidence‐based regimens have been specifically developed for KD, making the treatment of this disease particularly challenging for physicians. This article aims to provide the first comprehensive, up‐to‐date overview and analysis of treatment options employed for KD. A search of the PubMed/MEDLINE and Scopus databases was performed for articles regarding the treatment of KD, published in English between 1990 and 2019. Seventy‐three articles were identified, of which eighteen met the inclusion criteria. We discovered that a wide variety of treatment regimens for KD have been reported in the literature, including oral antibiotics, immunosuppressants, phototherapy, topical/systemic retinoids, topical keratolytics and various combination therapies, which include some of the aforementioned treatments, in conjunction with oral/topical/injectable steroids, emollients and/or antihistamines. The use of a combination regimen is the most commonly practiced therapeutic approach to KD. Topical corticosteroids and depot corticosteroid injections repeatedly appeared in many of the regimens encountered during our search. While no definitive recommendations can be made based on existing literature, this article provides physicians with a summative outline that can help guide management and be referenced when other treatment efforts fail. The increasing prevalence of renal disease, DM and other chronic diseases will inevitably lead to rising rates of KD in the upcoming years. While randomized controlled trials are greatly needed, novel antipruritic immunomodulatory drugs targeting specific interleukin receptors (IL‐4/13/31) and intracellular signalling (e.g. Janus kinase) pathways may have a potential role in the treatment of this disease.

[1]  Laura E. Abate,et al.  A systematic review of evidence‐based treatments for prurigo nodularis , 2019, Journal of the American Academy of Dermatology.

[2]  H. Dao,et al.  Chronic Pruritus: A Review of Neurophysiology and Associated Immune Neuromodulatory Treatments. , 2018, Skin therapy letter.

[3]  J. Pinto,et al.  Kyrle's disease associated with HIV infection, diabetes, and chronic kidney disease , 2018, Indian journal of pathology & microbiology.

[4]  T. Ruzicka,et al.  Clinical and molecular characterization and response to acitretin in three families with Sjögren‐Larsson syndrome , 2018, International journal of dermatology.

[5]  P. Gisondi,et al.  Kyrle’s disease effectively treated with oral isotretinoin , 2018, The Journal of dermatological treatment.

[6]  Akhila Lakshmikantha,et al.  Kyrle’s disease: a cutaneous manifestation of diabetes mellitus , 2017, BMJ Case Reports.

[7]  D. Paton Dupilumab: human monoclonal antibody against IL-4Rα for moderate to severe atopic dermatitis. , 2017, Drugs of today.

[8]  Y. Matsuzaki,et al.  Successful treatment of Kyrle disease with narrowband ultraviolet B , 2017, The Journal of dermatology.

[9]  S. Shimada,et al.  Efficacy of topical tacrolimus for treating Kyrle's disease , 2017, The Journal of dermatology.

[10]  Connie M. Rhee,et al.  US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  R. Verma,et al.  Kyrle's Disease Presenting in an Extensive Distribution along Lines of Blaschko , 2015, Indian Journal of Dermatology.

[12]  N. Diwan,et al.  Kyrle's disease in a patient of diabetes mellitus and chronic renal failure on dialysis , 2015, Journal of family medicine and primary care.

[13]  S. Jee,et al.  Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis. , 2014, Journal of the American Academy of Dermatology.

[14]  A. Metin,et al.  Clinicopathological features of 25 patients with acquired perforating dermatosis. , 2013, EJD. European journal of dermatology.

[15]  F. Persechino,et al.  Kyrle's Disease: Treatment with Minocycline and Topic Tacalcitol , 2013 .

[16]  T. Tsai,et al.  Kyrle’s disease successfully treated with allopurinol , 2011, International Journal of Dermatology.

[17]  H. Törmä Regulation of keratin expression by retinoids , 2011, Dermato-endocrinology.

[18]  K. Hari Kumar,et al.  Acquired perforating dermatoses in patients with diabetic kidney disease on hemodialysis , 2010, Hemodialysis international. International Symposium on Home Hemodialysis.

[19]  T. Tsuda,et al.  Tetracyclines Modulate Protease-Activated Receptor 2-Mediated Proinflammatory Reactions in Epidermal Keratinocytes , 2009, Antimicrobial Agents and Chemotherapy.

[20]  Qiang Zhou,et al.  Structures and biological functions of IL-31 and IL-31 receptors. , 2008, Cytokine & growth factor reviews.

[21]  I. Slim,et al.  Regression of skin lesions of Kyrle's disease with metronidazole in a diabetic patient. , 2007, The Journal of infection.

[22]  F. Port,et al.  Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  S. G. Shimada,et al.  Scratching behavior in mice induced by the proteinase-activated receptor-2 agonist, SLIGRL-NH2. , 2006, European journal of pharmacology.

[24]  M. Falagas,et al.  Regression of skin lesions of Kyrle's disease with clindamycin: implications for an infectious component in the etiology of the disease. , 2005, The Journal of infection.

[25]  C. Ihm,et al.  Acquired Perforating Dermatosis in Patients with Chronic Renal Failure and Diabetes Mellitus , 2004, Journal of Korean medical science.

[26]  Thomas A. Luger,et al.  Proteinase-Activated Receptor-2 Mediates Itch: A Novel Pathway for Pruritus in Human Skin , 2003, The Journal of Neuroscience.

[27]  M. Nilles,et al.  Erworbene reaktiv perforierende Dermatose bei Psoriasis vulgaris , 2001 .

[28]  C. Morton,et al.  Acquired perforating dermatosis in a British dialysis population , 1996, The British journal of dermatology.

[29]  R. Pisharody,et al.  Kyrle's disease : a cutaneous marker of renal disorder. , 1996, Indian Journal of Dermatology, Venereology and Leprology.

[30]  K. Lloyd,et al.  Kyrle's disease. Effectively treated with isotretinoin. , 1993, The Journal of the Florida Medical Association.

[31]  M. Melton,et al.  Perforating folliculitis in association with hemodialysis , 1982, The American Journal of dermatopathology.

[32]  V. S. Constantine,et al.  Kyrle's Disease: II. Histopathologic Findings in Five Cases and Review of the Literature , 1968 .

[33]  V. S. Constantine,et al.  Kyrle's Disease: I. Clinical Findings in Five Cases and Review of Literature , 1968 .

[34]  Connie M. Rhee,et al.  US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  C. Massone,et al.  Allopurinol in the treatment of acquired reactive perforating collagenosis* , 2013, Anais brasileiros de dermatologia.

[36]  P. Frosch,et al.  Successful treatment of acquired reactive perforating collagenosis with doxycycline. , 2002, Acta dermato-venereologica.